| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | 72.0 | ¤964,130 | US |
| JNJ | Johnson & Johnson | 63.4 | ¤586,738 | US |
| MRK | Merck & Co., Inc. | 63.3 | ¤294,956 | US |
| AMGN | Amgen Inc. | 65.0 | ¤204,485 | US |
| ABT | Abbott Laboratories | 45.1 | ¤202,023 | US |
| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| PODD | Insulet Corporation | 63.1 | ¤17,705 | US |
| ZBH | Zimmer Biomet Holdings, Inc. | 50.4 | ¤19,759 | US |
| DGX | Quest Diagnostics Incorporated | 54.0 | ¤23,483 | US |
| LH | Labcorp Holdings Inc. | 49.6 | ¤23,700 | US |
| STE | STERIS plc | 57.5 | ¤24,980 | IE |
| Symbol | Name | Grade | Times* | Country |
|---|---|---|---|---|
| AMGN | Amgen Inc. | 65.0 | 31 | US |
| LLY | Eli Lilly and Company | 72.0 | 26 | US |
| PFE | Pfizer Inc. | 52.1 | 24 | US |
| DGX | Quest Diagnostics Incorporated | 54.0 | 22 | US |
| ZTS | Zoetis, Inc. Class A | 62.6 | 22 | US |
| BMY | Bristol-Myers Squibb Company | 62.3 | 21 | US |
| JNJ | Johnson & Johnson | 63.4 | 21 | US |
| TMO | Thermo Fisher Scientific Inc. | 48.9 | 21 | US |
| RMD | ResMed Inc. | 71.3 | 19 | US |
| GILD | Gilead Sciences, Inc. | 71.0 | 18 | US |
| Average Market Cap | ¤142,253 |
| Median Market Cap | ¤81,475 |
| Avg. 3 Mo. Dollar Vol. | ¤699,603,181 |
| Avg. 3 Mo. Trading Vol. | 5,098,037 |
| Last Rebalance Date | 09/22/2025 |
| Companies Replaced | 10 |
| Biggest Sector Increase | Health Care |
| Biggest Sector Decrease | Health Care |
| Trailing P/E Ratio (12 Mo.) | 27.1 |
| Forward P/E Ratio (12 Mo.) | 19.9 |
| Price/Book Ratio | 5.0 |
| Avg. Revenue Chg. - 3 Yr | 17.2% |
| Avg. Op. Income Chg. - 3 Yr. | 24.7% |
| Avg. EPS Growth - 3 Yr. | 10.3% |
| Avg. EPS Growth - 1 Yr. | 11.6% |
| Avg. Operating Margin | 20.3% |
| Avg. LT Debt to Total Capital | 39.8% |
| Avg. Return on Equity | 18.1% |
| Dividend Yield | 0.9% |
| US Health Care Index | 57.48 |
| United States Of America | 90.0% |
| Ireland | 6.67% |
| Switzerland | 3.33% |
